Literature DB >> 16901709

Doxorubicin in experimental and clinical heart failure.

Stefan Christiansen1, Rüdiger Autschbach.   

Abstract

Doxorubicin-induced heart failure is a rare but serious illness due to the well-known treatment difficulties. Prevention strategies have not demonstrated the expected success and unfortunately, this specific type of heart failure does not respond to the usual medical therapy as other kinds of heart failure. Therefore, surgical procedures may be necessary in some patients. Cardiac transplantation is performed in most cases but it requires the cure of the neoplastic disease. This usually requires a recurrence-free interval of several years which is associated with a high attrition rate in these patients due to their cardiac disease. Therefore, other conservative and surgical treatment concepts were developed during the last years. This review presents the most common procedures and discusses their efficacy as well as their clinical applicability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16901709     DOI: 10.1016/j.ejcts.2006.06.024

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  25 in total

1.  Haploinsufficiency of target of rapamycin attenuates cardiomyopathies in adult zebrafish.

Authors:  Yonghe Ding; Xiaojing Sun; Wei Huang; Tiffany Hoage; Margaret Redfield; Sudhir Kushwaha; Sridhar Sivasubbu; Xueying Lin; Stephen Ekker; Xiaolei Xu
Journal:  Circ Res       Date:  2011-07-14       Impact factor: 17.367

2.  Antioxidant and antiproliferative effects of different solvent fractions from Terminalia belerica Roxb. fruit on various cancer cells.

Authors:  Tapasree Basu; Sourav Panja; Nikhil Baban Ghate; Dipankar Chaudhuri; Nripendranath Mandal
Journal:  Cytotechnology       Date:  2016-12-21       Impact factor: 2.058

3.  Alteration of Bax/Bcl-2 ratio contributes to Terminalia belerica-induced apoptosis in human lung and breast carcinoma.

Authors:  Nikhil Baban Ghate; Bibhabasu Hazra; Rhitajit Sarkar; Dipankar Chaudhuri; Nripendranath Mandal
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-01-08       Impact factor: 2.416

4.  Berberine sensitizes mutliple human cancer cells to the anticancer effects of doxorubicin in vitro.

Authors:  Nannan Tong; Jie Zhang; Youran Chen; Zhubo Li; Yonghuang Luo; Hua Zuo; Xiaoyan Zhao
Journal:  Oncol Lett       Date:  2012-03-14       Impact factor: 2.967

5.  Phosphorylation of IκBα at serine 32 by T-lymphokine-activated killer cell-originated protein kinase is essential for chemoresistance against doxorubicin in cervical cancer cells.

Authors:  Jung-Hwan Park; Dae-Sung Yoon; Hye-Jin Choi; Dae-Hyun Hahm; Sang-Muk Oh
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

6.  In vitro anticancer activity of Spondias pinnata bark on human lung and breast carcinoma.

Authors:  Nikhil Baban Ghate; Bibhabasu Hazra; Rhitajit Sarkar; Nripendranath Mandal
Journal:  Cytotechnology       Date:  2013-05-18       Impact factor: 2.058

7.  Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer.

Authors:  Shuang Liang; Richard C Brundage; Pamala A Jacobson; Anne Blaes; Mark N Kirstein
Journal:  Br J Clin Pharmacol       Date:  2016-06-03       Impact factor: 4.335

Review 8.  New and TALENted genome engineering toolbox.

Authors:  Jarryd M Campbell; Katherine A Hartjes; Timothy J Nelson; Xiaolei Xu; Stephen C Ekker
Journal:  Circ Res       Date:  2013-08-16       Impact factor: 17.367

9.  Overexpression of Nrdp1 in the heart exacerbates doxorubicin-induced cardiac dysfunction in mice.

Authors:  Yuan Zhang; Yu-Ming Kang; Cui Tian; Yong Zeng; Li-Xin Jia; Xu Ma; Jie Du; Hui-Hua Li
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

10.  Overexpression of angiopoietin-1 reduces doxorubicin-induced apoptosis in cardiomyocytes.

Authors:  Danyang Ren; Quan Zhu; Jiantao Li; Tuanzhu Ha; Xiaohui Wang; Yuehua Li
Journal:  J Biomed Res       Date:  2012-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.